Cargando…

Randomized Controlled Study Comparing Efficacy and Toxicity of Weekly vs. 3-Weekly Induction Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma

Background: Head and Neck Cancer is a major public health problem in India, majority of which are lifestyle related, male predominant requiring dedicated infrastructure and human resource. The 5-year survival is 59% for all stages combined and only 45% in patients with locally advanced inoperable he...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tousif, Devale, Sarathy, Vinu, Kumar, Rajesh, Naik, Radheshyam
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7424062/ https://www.ncbi.nlm.nih.gov/pubmed/32850394 http://dx.doi.org/10.3389/fonc.2020.01284

Ejemplares similares

Addition of Nimotuzumab to Standard TPF Regimen in Locally Advanced Head and Neck Cancer: A Single Institutional Study
por: Koramati, Samuel Luke, et al.
Publicado: (2021)

Combination Strategies to Augment Immune Check Point Inhibitors Efficacy - Implications for Translational Research
por: Varayathu, Hrishi, et al.
Publicado: (2021)

Predictive Biomarkers for Response and Toxicity of Induction Chemotherapy in Head and Neck Cancers
por: Boguszewicz, Łukasz
Publicado: (2022)

Randomized trial on acute toxicities of weekly vs three‐weekly cisplatin‐based chemoradiation in head and neck cancer
por: Ameri, Ahmad, et al.
Publicado: (2021)

Multicenter phase II study of weekly docetaxel, cisplatin, and S-1 (TPS) induction chemotherapy for locally advanced squamous cell cancer of the head and neck
por: Bae, Woo Kyun, et al.
Publicado: (2013)

Paclitaxel Plus Cetuximab as Induction Chemotherapy for Patients With Locoregionally Advanced Head and Neck Squamous Cell Carcinoma Unfit for Cisplatin-Based Chemotherapy
por: Marín-Jiménez, Juan A., et al.
Publicado: (2022)

Weekly vs. 3-weekly paclitaxel, carboplatin, and cetuximab (PCC) in recurrent/metastatic head and neck cancer
por: Geraghty, Leeann, et al.
Publicado: (2021)

The Slippery Role of Induction Chemotherapy in Head and Neck Cancer: Myth and Reality
por: Ferrari, Daris, et al.
Publicado: (2020)

An Update on Advances in COVID-19 Laboratory Diagnosis and Testing Guidelines in India
por: Kumar, K. S. Rajesh, et al.
Publicado: (2021)

Radiotherapy potentiation with weekly cisplatin compared to standard every 3 weeks cisplatin chemotherapy for locoregionally advanced head and neck squamous cell carcinoma
por: Fayette, Jérôme, et al.
Publicado: (2015)

Primary Concurrent Chemoradiation in Head and Neck Cancers with Weekly Cisplatin Chemotherapy: Analysis of Compliance, Toxicity and Survival
por: Iqbal, Muhammad Shahid, et al.
Publicado: (2016)

Weekly Paclitaxel, Carboplatin, and Cetuximab as First-Line Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma for Patients Ineligible to Cisplatin-Based Chemotherapy: A Retrospective Monocentric Study in 60 Patients
por: Carinato, Hélène, et al.
Publicado: (2021)

A Case of Cardiac Tamponade in a Patient with Metastatic Renal Cell Carcinoma on Pazopanib Treatment
por: Sarathy, Vinu, et al.
Publicado: (2020)

The comparison of acute toxicity in 2 treatment courses: Three-weekly and weekly cisplatin treatment administered with radiotherapy in patients with head and neck squamous cell carcinoma
por: Mackiewicz, Jacek, et al.
Publicado: (2017)

Safety and efficacy of weekly versus three-weekly paclitaxel plus platinum neoadjuvant chemotherapy in patients with locally advanced squamous cell head and neck carcinoma: A pilot study
por: Mathur, Akash, et al.
Publicado: (2018)

Comparison of Carboplatin With 5-Fluorouracil vs. Cisplatin as Concomitant Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma
por: Hanemaaijer, Saskia H., et al.
Publicado: (2020)

Immunotherapy for Head and Neck Cancer: A Paradigm Shift From Induction Chemotherapy to Neoadjuvant Immunotherapy
por: Shibata, Hirofumi, et al.
Publicado: (2021)

3-weekly or weekly cisplatin concurrently with radiotherapy for patients with squamous cell carcinoma of the head and neck – a multicentre, retrospective analysis
por: Helfenstein, Seth, et al.
Publicado: (2019)

Induction chemotherapy combined with immunotherapy in locally advanced head and neck squamous cell carcinoma
por: Li, Xia, et al.
Publicado: (2021)

Predictive factors of toxicity of TPF induction chemotherapy for locally advanced head and neck cancers
por: Bernadach, Maureen, et al.
Publicado: (2021)

Predictive Value of Cetuximab-Induced Skin Toxicity in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NECK
por: Uozumi, Shinya, et al.
Publicado: (2018)

Automated tracking of morphologic changes in weekly magnetic resonance imaging during head and neck radiotherapy
por: Aliotta, Eric, et al.
Publicado: (2023)

Predictive Value of Multiparametric MRI for Response to Single-Cycle Induction Chemo-Immunotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma
por: Hellwig, Konstantin, et al.
Publicado: (2021)

Exosomes in Head and Neck Squamous Cell Carcinoma
por: Xiao, Cheng, et al.
Publicado: (2019)

Severe skin toxicity due to weekly paclitaxel administration
por: Kate, Shruti, et al.
Publicado: (2015)

Comparison of Acute and Late Toxicity of Two Regimens of 3- and 5-Week Concomitant Boost Prone IMRT to Standard 6-Week Breast Radiotherapy
por: Raza, Shahzad, et al.
Publicado: (2012)

Cisplatin Weekly Versus Every 3 Weeks Concurrently with Radiotherapy in the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinomas: What Is the Best Dosing and Schedule?
por: Mashhour, Karim, et al.
Publicado: (2020)

Combined Nimotuzumab with Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma
por: Thai Hoa, Nguyen Thi, et al.
Publicado: (2020)

Comparison of Hematologic Toxicity and Bone Marrow Compensatory Response in Head and Neck vs. Cervical Cancer Patients Undergoing Chemoradiotherapy
por: Vitzthum, Lucas K., et al.
Publicado: (2020)

Modified Weekly Cisplatin-Based Chemotherapy Is Acceptable in Postoperative Concurrent Chemoradiotherapy for Locally Advanced Head and Neck Cancer
por: Lu, Hsueh-Ju, et al.
Publicado: (2015)

Weekly Docetaxel, Cisplatin, and Cetuximab in Palliative Treatment of Patients with Squamous Cell Carcinoma of the Head and Neck
por: Trieu, Vanessa, et al.
Publicado: (2018)

Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma: A Question of Belief
por: Karabajakian, Andy, et al.
Publicado: (2018)

Weekly chemotherapy as first line treatment in frail head and neck cancer patients in the immunotherapy era
por: Botticelli, Andrea, et al.
Publicado: (2021)

Weekly versus every-three-weeks platinum-based chemoradiation regimens for head and neck cancer
por: Melotek, James M., et al.
Publicado: (2016)

Molecular Mechanisms of Chemotherapy Resistance in Head and Neck Cancers
por: Kanno, Yuzuka, et al.
Publicado: (2021)

MTHFD2 Blockade Enhances the Efficacy of β-Lapachone Chemotherapy With Ionizing Radiation in Head and Neck Squamous Cell Cancer
por: Shukla, Kirtikar, et al.
Publicado: (2020)

Hypermagnesemia in critically ill patients with cancer: A case report
por: Krupesh, Vijay Raju, et al.
Publicado: (2021)

Concurrent Chemoradiation with Low-Dose Weekly Cisplatin in Locally Advanced Stage IV Head and Neck Squamous Cell Carcinoma
por: Kang, Myoung Hee, et al.
Publicado: (2015)

Effect of definitive hypo-fractionated radiotherapy concurrent with weekly cisplatin in locally advanced squamous cell carcinoma of the head and neck
por: Abdelhafiz, Nora, et al.
Publicado: (2023)

P34.01 6-Weekly vs 3-Weekly Pembrolizumab – Toxicities and Tolerance in The COVID-era
por: Douglas, C., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_beudkmj99ce5vaq47jfnsr2ogl